Modern concepts for the prediction of type 1 diabetes

Experimental and Clinical Endocrinology and Diabetes

Volumn 109, Issue SUPPL. 2, 2001, Pages

  Seissler, J ^a   Hatziagelaki, E ^a   Scherbaum, W A ^a  

^a LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

Author keywords

Autoantibodies; Prediction; Type 1 diabetes

Indexed keywords

AUTOANTIBODY;

ARTICLE; GENETIC LINKAGE; GENETIC PREDISPOSITION; GENETIC SCREENING; GENOTYPE; HLA TYPING; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PRIORITY JOURNAL; RISK ASSESSMENT;

AUTOANTIBODIES; AUTOANTIGENS; DIABETES MELLITUS, TYPE 1; FORECASTING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; T-LYMPHOCYTES;

EID: 0034977784     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-18590     Document Type: Article

References (74)

1. Identification and characterization of glima 38, a glycosylated islet cell membrane antigen, which together with GAD65 and IA2 marks the early phases of autoimmune response in type 1 diabetes
2. Putative environmental factors in type 1 diabetes
3. Imogen 38: A novel 38-kD islet mitochondrial autoantigen recognized by T cells from a newly diagnosed type 1 diabetic patient
4. The pathogenesis of insulin-dependent diabetes mellitus
5. Cellular immunity to a determinant common to glutamate decarboxylase and coxsackie virus in insulin-dependent diabetes
6. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase
7. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies
8. Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives
9. Interactions of age, islet cell antibodies, insulin autoantibodies, and first-phase insulin response in predicting risk of progression to IDDM in ICA+ relatives: The ICARUS data set. Islet Cell Antibody Register Users Study
10. Prediction of IDDM in the general population: Strategies based on combinations of autoantibody markers
11. Epidemiology and immunogenetic background of islet cell antibody-positive nondiabetic schoolchildren. Ulm-Frankfurt population study
12. Quantification of islet-cell antibodies and prediction of insulin-dependent diabetes
13. Islet autoantibody markers in IDDM: Risk assessment strategies yielding high sensitivity
14. Validity of screening for individuals at risk for type 1 diabetes by combined analysis of antibodies to recombinant proteins
15. GADIA2-combi determination as first-line screening for improved prediction of type 1 diabetes in relatives
16. Autoimmunity to the GM2-1 islet ganglioside before and at the onset of type 1 diabetes
17. Cellular immune response to diverse islet cell antigens in IDDM
18. The relationship between humoral and cellular immunity to IA-2 in IDDM
19. Prediction of type 1 diabetes postpartum in patients with gestational diabetes mellitus by combined islet cell autoantibody screening: A prospective multicenter study
20. Islet cell antibody-positive relatives with human leukocyte antigen DQA1*0102, DQB1*0602: Identification by the Diabetes Prevention Trial-type 1
21. Islet cell antibodies identify latent type 1 diabetes in patients aged 35-75 years at diagnosis
22. Autoantibodies in IDDM primarily recognize the 65,000-M(r) rather than the 67,000-M(r) isoform of glutamic acid decarboxylase
23. Genetic heterogeneity of autoimmune diabetes: Age of presentation in adults is influenced by HLA DRB1 and DQB1 genotypes (UKPDS 43)
24. The value of islet cell antibody in predicting secondary failure of oral hypoglycaemic agent therapy in diabetes mellitus
25. Th1-like cytokine production profile and individual specific alterations in TCRBV-gene usage of T cells from newly diagnosed type 1 diabetes patients after stimulation with beta-cell antigens
26. Cytokine secretion patterns in twins discordant for type 1 diabetes
27. Diseaseassociated autoantibodies as surrogate markers of type 1 diabetes in young children at increased genetic risk
28. Islet cell antibodies are less predictive of IDDM among unaffected children in the general population than in sibs of children with diabetes
29. Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM
30. Benign versus destructive insulitis
31. Insulin and islet cell autoantibodies as time-dependent covariates in the development of insulin-dependent diabetes: A prospective study in relatives
32. Prediction of insulin-dependent diabetes mellitus in siblings of children with diabetes. A population-based study
33. Genetic markers, humoral autoimmunity, and prediction of type 1 diabetes in siblings of affected children
34. Molecular cloning and identification of a receptor-type protein tyrosine phosphatase, IA-2, from human insulinoma
35. Concordance between twins for beta-cell autoimmunity
36. Detection of autoantibodies to the diabetes-associated antigen IA-2 by a sensitive enzyme-linked immunosorbent assay
37. Immunodominant epitopes of glutamic acid decarboxylase 65 and 67 in insulin-dependent diabetes mellitus
38. T cell reactivity to DR*0401-and DQ*0302-binding peptides of the putative autoantigen IA-2 in type 1 diabetes
39. Islet cell autoantigen 69 antibodies in
40. Antibodies to the tyrosine phosphatase-like protein IA-2 are highly associated with IDDM, but not with autoimmune endocrine diseases or stiff man syndrome
41. Pancreatic islet cell cytoplasmic antibody in diabetes is represented by antibodies to islet cell antigen 512 and glutamic acid decarboxylase
42. Immunoglobulin G insulin autoantibodies in Baby-DIAB offspring appear postnatally: Sensitive early detection using a protein A/G-based radiobinding assay
43. GAD antibodies in NIDDM. Ten-year follow-up from the diagnosis
44. Detection of autoantibodies to the pancreatic islet heat shock protein 60 in insulin-dependent diabetes mellitus
45. Two-step islet autoantibody screening for risk assessment of type 1 diabetes in relatives
46. Relationship of the 37,000- and 40,000-M(r) tryptic fragments of islet antigens in insulin-dependent diabetes to the protein tyrosine phosphatase-like molecule IA-2 (ICA512)
47. Autoreactive and immunoregulatory T-cell subsets in insulin-dependent diabetes mellitus
48. Islet cell antigen 512 is a diabetes-specific islet autoantigen related to protein tyrosine phosphatases
49. Betacell autoantibodies in infants and toddlers without IDDM relatives: Diabetes autoimmunity study in the young (DAISY)
50. Cytoplasmic islet cell antibodies recognize distinct islet antigens in IDDM but not in stiff man syndrome
51. A prospective study of the development of diabetes in relatives of patients with insulin-dependent diabetes
52. T-cell reactivity to beta-cell membrane antigens associated with beta-cell destruction in IDDM
53. Autoreactive T-cell responses in insulin-dependent (type 1) diabetes mellitus. Report of the first international workshop for the standardisation of T cell assays
54. Autoantibodies associated with type 1 diabetes mellitus persist after diagnosis in children
55. Islet cell antibodies predict insulindependent diabetes in United States school age children as powerfully as in unaffected relatives
56. Immunology in diabetes: An update
57. Epidemiologic studies of the recognition of the preclinical phase of type 1 diabetes in schoolchildren
58. Prevalence of autoantibodies to the 65- and 67-kD isoforms of glutamate decarboxylase in insulin-dependent diabetes mellitus
59. Association between antibodies to the MR 67,000 isoform of glutamate decarboxylase (GAD) and type 1 (insulin-dependent) diabetes mellitus with coexisting autoimmune polyendocrine syndrome type II
60. Combined screening for autoantibodies to IA-2 and antibodies to glutamic acid decarboxylase in first degree relatives of patients with IDDM
61. Immunological heterogeneity in type 1 diabetes: Presence of distinct autoantibody patterns in patients with acute onset and slowly progressive disease
62. High frequncy of diabetesspecific autoantibodies in parents of children with type 1 diabetes
63. T-cell insulitis found in anti-GAD65+ diabetes with residual beta-cell function. A case report
64. ICA 512, an autoantigen of type 1 diabetes, is an intrinsic membrane protein of neurosecretory granules
65. Genetic analysis of type 1 diabetes using whole genome approaches
66. UKPDS 25: Autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes
67. Concentration of insulin autoantibodies at onset of type 1 diabetes. Inverse log-linear correlation with age
68. Prediction of type 1 diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/ IA-2 autoantibodies
69. Combined analysis and single-step detection of GAD 65 and IA2 autoantibodies in IDDM can replace the histochemical islet cell antibody test
70. A novel micro-assay for insulin autoantibodies
71. Early expression of antiinsulin autoantibodies of humans and the NOD mouse: Evidence for early determination of subsequent diabetes
72. Life-table analysis of progression to diabetes of anti-insulin autoantibodypositive relatives of individuals with type 1 diabetes
73. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: The 2-year analysis of the German Baby-DIAB Study
74. Latent autoimmune diabetes mellitus in adults (LADA): The role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency